MyDekla Daclatasvir Dihydrochloride Tablets, 60 mg

Banking upon in-depth domain knowledge and years of vast experience, we are engaged in offering Mydekla Tablets (Daclatasvir Dihydrochloride 60mg Tablets). These Mydekla Tablets are used for the treatment of a patient with chronic hepatitis C virus (HCV) genotype 3 infection. Our expert agents procure these tablets from the trusted vendors of the market. Mydekla Tablets are tested on defined quality parameters before packing in medical grade materials. We offer Daclatasvir Dihydrochloride 60mg Tablets at reasonable prices. Mydekla Tablets Features: Accurate composition A low indication of side effects Inhibitor of non-structural protein 5A Mydekla Tablets Description: Mydekla 60 is an inhibitor of non-structural protein 5A (NS5A). Each film-coated tablet contains Daclatasvir equivalent to Daclatasvir 30 mg or 60 mg. Mydekla Tablets Indications And Usage: Mydekla 60 is indicated in combination with Sofosbuvir for the treatment of patient with chronic hepatitis C virus (HCV) genotype 3 infection. Mydekla Tablets Dosage And Administration: Treatment with Mydekla 60 should be initiated and monitored by a physician experienced in the management of chronic hepatitis C. The recommended dose of Mydekla 60 is 60 mg once daily to be taken orally with or without meals. Mydekla 60 must be administered in combination with other medical products. The Packages inserts of the medicinal products in the regimen should also be consulted before initiation of therapy with Mydekla 60. Recommended regimens and treatment duration are provided below. Dose modification, interruption and discontinuation Dose modification of Mydekla 60 mg tablets to manage adverse reactions is not recommended.